I've shared some further thoughts on @jeffsparks SAIL-RA study and its finding of the strong association of RA-ILD with disease activity in early RA. And of course couldn't resist going on a tangent about the ACR ILD guidelines! #ACR24 @RheumNow https://t.co/UUDbWw38Im

• Disease Activity in RA-ILD | RheumNow

A key practice changing study (I hope) from #ACR24 has been the preCARA study. Fertility increases with aggressive disease control. My video on this study is up now on @RheumNow https://t.co/Pf3rdTHbOJ

• Treat-to-Target Improves Fertility in Women with RA | RheumNow

The TAPIR study presented at #ACR24 may not be as attention grabbing as others like SELECT-GCA, but in my opinion it is arguablyone of the most important ANCA-vasculitis studies ever. I've shared some further thoughs in an article on @RheumNow https://t.co/mImAE8ezSQ

• RIP to Glucocorticoids in GPA | RheumNow

RheumNow Day 2 Recap: ACR Convergence 2024 Highlights https://t.co/YAwOEaNsWs

• Dr. John Cush

RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty

We saw evidence for JAK use in GCA this conference... what about IL-1 inhibition? Double-blind RCT: Anakinra vs. PBO w/ similar GC taper in GCA pt NO difference in relapse rate at 26, 52 wks despite addition of Anakinra @RheumNow #ACR24 Abst1699 https://t.co/gUb0gGJjTG

• https://x.com/Dr_Brian_MD/status/1858268878658514984/photo/1

VERY exciting SLE update from Fava et al. Machine learning used to generate urinary protein panel predictive of intra-renal inflammation BETTER than serum biomarkers C3, C4, dsDNA Also monitoring tool for renal response. Outstanding. @RheumNow #ACRbest #ACR24 https://t.co/YXgKrSU4UQ

• https://x.com/Dr_Brian_MD/status/1858272797983977838/photo/1
• https://x.com/Dr_Brian_MD/status/1858272797983977838/photo/1

To stop tsDMARD / bDMARD To improve #COVIDVACCINE response in those w several previous #COVID19 #vaccinations is NOT necessary This will change my practice! #ACR24 @RheumNow @ACRheum https://t.co/WXeqMOEfuA

• https://twitter.com/healiorheum/status/1858268880310874586

What a result!!! Crowed split 49% against and 51% for MCTD as a unique disease entity Given pre-debate poll of >70% for MCTD, looks like an overall win for the “NOT” group Fantastic session from all the presenters @RheumNow #ACR24 https://t.co/GgTVQ1VNWP

• https://x.com/Dr_Brian_MD/status/1858266822073581805/photo/1

Super helpful results from COVER study, holding JAK or IL17 for COVID boosters Antibody titers went up regardless of holding Holding caused flares (14-25% increase!) Pretty clear message; continue JAK / IL17 #ACR24 @RheumNow Abstr#1718 #ACRbest https://t.co/Mf89dWrRWz

• https://x.com/EBRheum/status/1858267620316688737/photo/1

Would be helpful for us (and pts) to better understand rimmunotherapy agent specific risk on subsequent GCA/PMR AFTRER propensity matching of >7k pt on combo nivolumab/ipilimumab compared to pembrolizumab: - PMR RR 3.8x N/I vs. P - no diff in GCA risk @RheumNow #ACR24 https://t.co/IF4Gh7Cumd

• https://x.com/Dr_Brian_MD/status/1858268380714664309/photo/1

🔶Clinical Year in Review #ACR24 🔶 Talk By @MHPillingerMD • Review some of the most impactful studies in Rheumatology from the past year! #RheumTwitter #Rheumatology https://t.co/1ULDB2l4gX

• https://x.com/MithuRheum/status/1858157622219641261/photo/1

The anti-MCTD group strikes back Of cohort of over 1,000 RNP+ pt, only 17 clinically diagnosed with MCTD Majority of patients, despite potential overlap, treated for other primary rheum dz @RheumNow #ACR24 https://t.co/vkQ6UPs34y

• https://x.com/Dr_Brian_MD/status/1858261782160351458/photo/1

Older RA patients in RISE with high disease activity show a higher incidence of hip and major osteoporotic fractures. Practice T2T and monitor bone health closely! #ACR24 @RheumNow ABST#1748 https://t.co/7MCAIrfXhp

• https://x.com/JihaRheum/status/1858263593927778331/photo/1